Status:
UNKNOWN
Accelerated Body Diffusion-Weighted MRI Using Artificial Intelligence
Lead Sponsor:
Royal Marsden NHS Foundation Trust
Conditions:
Cancer
Eligibility:
All Genders
18+ years
Brief Summary
Whole-body diffusion-weighted MRI (WBDWI) is a non-invasive tool used for staging and response evaluation in oncologic practice and is at the core of emerging response criteria in advanced prostate an...
Eligibility Criteria
Inclusion
- Patients who have received one of the following MRI examinations (scan type shown in parentheses):
- Multiple Myeloma (whole-body)
- Metastatic Prostate Cancer (whole-body)
- Metastatic Breast Cancer (whole-body)
- Liver Metastases (stacked abdomen/pelvis)
- Pancreatic Cancer (stacked abdomen/pelvis)
- Gynaecological Cancers (stacked abdomen/pelvis)
- Gastrointestinal Cancers (stacked abdomen/pelvis)
- Primary Prostate Cancers (multiparametric Prostate exam)
- Patients who have received one of the above-mentioned scan types using a modified clinical multi-direction diffusion-weighted (MDDW) MRI protocol as part of standard of care.
- Exclusion Criteria:
- No exclusion criteria as this is a retrospective data study only.
Exclusion
Key Trial Info
Start Date :
May 6 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 1 2025
Estimated Enrollment :
450 Patients enrolled
Trial Details
Trial ID
NCT05380609
Start Date
May 6 2022
End Date
April 1 2025
Last Update
May 19 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Radiology, The Royal Marsden NHS Foundation Trust
Sutton, Surrey, United Kingdom, SM2 5PT